The Women’s Health Products Working Group (WHPWG) is an advisory forum that supports collaboration between the Therapeutic Goods Administration (TGA) and other stakeholders, including health professionals, academia and people accessing the health system.
For the past 2 years Alliance Chair, Bonney Corbin, has been involved in the WHPWG, supporting advocacy on issues such as health-product amendments linked to Asherman’s Syndrome (led by consumer leaders and groups including Asherman Syndrome Australia and New Zealand).
For instance, we’re working with Deb Loxton, via our partnership with Women’s Health Research, Translation and Impact Network (WHRTN), to generate new data on Asherman’s using the Australian Longitudinal Study on Women’s Health (ALSWH) These findings will be presented to the TGA in October 2025.
We’ve also been tracking the TGA’s Medicines Repurposing Program (running from 1 March 2024 to 30 June 2027), which offers regulatory fee waivers for sponsors submitting new indications for existing medicines. This is an important step towards reducing preventable pain caused by outdated policy and regulatory barriers.
By addressing gendered barriers linked to health products, including being informed by those with lived experience and voices from women’s health services, we can continue advancing gender equity in health.
Learn more about the Medicines Repurposing Program | Therapeutic Goods Administration (TGA).
Become an Alliance member to participate in future advocacy opportunities.
